Kite’s CAR-T Therapy Makes It Back Onto EMA’s PRIME, Along With Three New Products

 
• By Neena Brizmohun
  
3d illustration of T cells or cancer cells
Kite's CAR-T therapy is among the four new products accepted onto the PRIME scheme

More from Market Access

More from Pink Sheet